BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cipla
Johnson and Johnson
Federal Trade Commission
Colorcon
Chubb
Express Scripts
Daiichi Sankyo
Farmers Insurance
Harvard Business School

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,618,109

« Back to Dashboard

Which drugs does patent 8,618,109 protect, and when does it expire?

Patent 8,618,109 protects REXULTI and is included in one NDA.

This patent has twenty-six patent family members in twenty-five countries.
Summary for Patent: 8,618,109
Title:Piperazine-substituted benzothiophenes for treatment of mental disorders
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001##
Inventor(s): Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP)
Assignee: Otsuka Parmaceutical Co., Ltd. (Tokyo, JP)
Application Number:13/688,108
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,618,109

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-001 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-002 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-003 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-006 Jul 10, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,618,109

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-116698Apr 14, 2005

Non-Orange Book US Patents Family Members for Patent 8,618,109

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,839,637 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
7,888,362 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
8,349,840 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
9,480,686 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
9,206,167 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,618,109

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I320783 ➤ Subscribe
Taiwan 200716619 ➤ Subscribe
Slovenia 1869025 ➤ Subscribe
Russian Federation 2402549 ➤ Subscribe
Russian Federation 2007142023 ➤ Subscribe
Portugal 1869025 ➤ Subscribe
Malaysia 142746 ➤ Subscribe
Mexico 2007012626 ➤ Subscribe
South Korea 100937623 ➤ Subscribe
South Korea 20080002817 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Dow
McKinsey
US Department of Justice
Express Scripts
Fuji
Cantor Fitzgerald
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot